Antibe Therapeutics (ATBPF) Short Interest Ratio & Short Volume $0.22 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Antibe Therapeutics Short Interest DataAntibe Therapeutics (ATBPF) has a short interest of 8,600 shares. This marks a -86.79% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 27,352 shares to cover all short positions.Current Short Interest8,600 sharesPrevious Short Interest65,100 sharesChange Vs. Previous Month-86.79%Dollar Volume Sold Short$1,854.16Short Interest Ratio0.0 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares52,981,000 sharesPercentage of Shares Shorted0.02%Today's Trading Volume0 sharesAverage Trading Volume27,352 sharesToday's Volume Vs. Average0% Short Selling Antibe Therapeutics? Sign up to receive the latest short interest report for Antibe Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATBPF Short Interest Over TimeATBPF Days to Cover Over TimeATBPF Percentage of Float Shorted Over Time Antibe Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/20258,600 shares $1,854.16 -86.8%N/A0 $0.22 1/15/202565,100 shares $14,035.56 No ChangeN/A0 $0.22 12/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 12/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 11/30/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 11/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 10/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 10/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 Get the Latest News and Ratings for ATBPF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 8/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 6/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 6/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 4/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 4/15/202465,100 shares $14,035.56 +1,934.4%N/A0.7 $0.22 3/31/20243,200 shares $1,070.40 -64.0%N/A0.1 $0.33 3/15/20248,900 shares $2,891.61 -73.1%N/A0.1 $0.32 2/29/202433,100 shares $23,653.26 +234.3%N/A0.5 $0.71 2/15/20249,900 shares $6,811.20 No ChangeN/A0.6 $0.69 1/15/202410,400 shares $8,112.00 -9.6%N/A1.4 $0.78 12/31/202311,500 shares $7,843.00 +121.2%N/A0.7 $0.68 12/15/20235,200 shares $3,571.88 -17.5%N/A1.1 $0.69 11/30/20236,300 shares $3,433.50 -54.0%N/A0.8 $0.55 11/15/202313,700 shares $7,521.30 +17.1%N/A0.1 $0.55 10/31/202311,700 shares $5,382.00 -27.8%N/A0.2 $0.46 10/15/202316,200 shares $5,799.60 +211.5%N/A1.7 $0.36 9/30/20235,200 shares $1,863.06 -24.6%N/A0.2 $0.36 9/15/20236,900 shares $2,829.00 -76.4%N/A0.3 $0.41 8/31/202329,200 shares $11,554.44 -22.8%N/A1.1 $0.40 8/15/202337,800 shares $15,498.00 +563.2%N/A1.5 $0.41 7/31/20235,700 shares $2,053.14 -8.1%N/A0.4 $0.36 7/15/20236,200 shares $2,156.98 No ChangeN/A2.8 $0.35 6/30/20236,200 shares $2,170.00 -7.5%N/A2.6 $0.35 6/15/20236,700 shares $2,517.19 -71.7%N/A1.6 $0.38 5/31/202323,700 shares $8,752.41 +203.9%N/A1.3 $0.37This Crypto Is Set to Explode in February (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 5/15/20237,800 shares $2,934.36 -27.8%N/A0.6 $0.38 4/30/202310,800 shares $4,342.68 -6.9%N/A3.1 $0.40 4/15/202311,600 shares $4,637.68 -78.6%N/A3.6 $0.40 3/31/202354,100 shares $23,766.13 -1.3%N/A2.5 $0.44 3/15/202354,800 shares $20,643.16 +260.5%N/A1.2 $0.38 2/28/202315,200 shares $5,668.08 -37.5%N/A1.7 $0.37 2/15/202324,300 shares $10,529.19 +22.7%N/A4.9 $0.43 1/31/202319,800 shares $8,401.14 +94.1%N/A0.8 $0.42 1/15/202310,200 shares $5,115.81 -56.8%N/A4.3 $0.50 12/30/202223,600 shares $7,622.80 -23.1%N/A2.5 $0.32 12/15/202230,700 shares $11,666.00 +44.8%N/A2.8 $0.38 11/30/202221,200 shares $7,420.00 +32.5%N/A3.2 $0.35 11/15/202216,000 shares $5,912.00 +3.9%N/A1.3 $0.37 10/31/202215,400 shares $5,998.30 +12.4%N/A3.1 $0.39 10/15/202213,700 shares $5,555.35 -8.7%N/A3 $0.41 9/30/202215,000 shares $6,718.50 -41.4%N/A1.1 $0.45 9/15/202225,600 shares $12,170.24 -13.8%N/A2.8 $0.48 8/31/202229,700 shares $14,362.92 -15.1%N/A2.3 $0.48 8/15/202235,000 shares $17,570.00 -39.2%N/A3.3 $0.50 7/31/202257,600 shares $25,920.00 -26.9%N/A20.6 $0.45 7/15/202278,800 shares $37,248.76 +3.8%N/A17.1 $0.47 6/30/202275,900 shares $35,832.39 -5.8%N/A5.2 $0.47 6/15/202280,600 shares $38,833.08 +2.8%N/A6.3 $0.48 5/31/202278,400 shares $42,696.64 +5.0%N/A6.2 $0.54 5/15/202274,700 shares $39,591.00 +48.8%N/A6.2 $0.53 4/30/202250,200 shares $28,011.60 +8.9%N/A7 $0.56 4/15/202246,100 shares $27,293.51 +45.9%N/A3.7 $0.59 3/31/202231,600 shares $20,066.00 +3.3%N/A2.4 $0.64 3/15/202230,600 shares $17,448.12 -23.7%N/A1.6 $0.57 2/28/202240,100 shares $23,454.49 +74.4%N/A1.1 $0.58 2/15/202223,000 shares $12,811.00 +57.5%N/A1.5 $0.56 1/31/202214,600 shares $7,678.14 +630.0%N/A0.2 $0.53 1/15/20222,000 shares $1,115.80 -66.1%N/A0.1 $0.56 12/31/20215,900 shares $3,043.81 -65.7%N/A0.1 $0.52 12/15/202117,200 shares $8,536.36 -71.4%N/A0.4 $0.50 11/30/202160,100 shares $32,737.67 -41.1%N/A1.6 $0.54 11/15/2021102,000 shares $72,644.40 -42.3%N/A0.7 $0.71 10/29/2021176,800 shares $114,725.52 +665.4%N/A1.2 $0.65 10/15/202123,100 shares $18,225.90 +725.0%N/A0.4 $0.79 9/30/20212,800 shares $2,640.40 +180.0%N/A0 $0.94 9/15/20211,000 shares $948.40 +11.1%N/A0 $0.95 8/31/2021900 shares $900.00 -96.4%N/A0 $1.00 8/13/202124,700 shares $25,935.00 -88.2%N/A0.1 $1.05 7/30/2021208,400 shares $561,638.00 +10.7%N/A6.6 $2.70 7/15/2021188,200 shares $513,409.60 -0.1%N/A9.6 $2.73 6/30/2021188,300 shares $559,251.00 -3.7%N/A5.8 $2.97 6/15/2021195,500 shares $602,218.20 -8.2%N/A5.5 $3.08 5/28/2021212,900 shares $724,924.50 +8.0%N/A11 $3.41 5/14/2021197,200 shares $646,816.00 -5.6%N/A8.2 $3.28 4/30/2021208,900 shares $714,458.89 +6.8%N/A5.8 $3.42This Crypto Is Set to Explode in February (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 4/15/2021195,600 shares $708,072.00 -12.6%N/A9.5 $3.62 3/31/2021223,700 shares $883,615.00 +41.5%N/A1.8 $3.95 3/15/2021158,100 shares $623,388.30 -54.4%N/A3.2 $3.94 2/26/2021346,600 shares $1.50 million +439.9%N/A2 $4.34 2/12/202164,200 shares $301,098.00 -17.3%N/A0.5 $4.69 1/29/202177,600 shares $219,297.60 +21.1%N/A1.8 $2.83 12/31/202028,600 shares $89,518.00 No ChangeN/A0.5 $3.13 11/30/202030,700 shares $9,513.93 +332.4%N/A0.1 $0.31 11/15/20207,100 shares $2,188.93 -64.5%N/A0.1 $0.31 10/30/202020,000 shares $4,800.00 No ChangeN/A0.2 $0.24 10/15/202020,000 shares $5,342.00 +52.7%N/A0.2 $0.27 9/30/202013,100 shares $3,445.30 No ChangeN/A0 $0.26 8/31/20201,300 shares $388.96 -93.1%N/A0 $0.30 8/14/202018,900 shares $5,934.60 -44.9%N/A0 $0.31 7/31/202034,300 shares $9,569.70 +2,350.0%N/A0.1 $0.28 7/15/20201,400 shares $408.52 -92.4%N/A0 $0.29 6/30/202018,300 shares $5,574.18 -36.2%N/A0 $0.30 6/15/202028,700 shares $10,705.10 +135.3%N/A0 $0.37 5/29/202012,200 shares $3,782.00 +281.3%N/A0.1 $0.31 5/15/20203,200 shares $1,856.00 -98.3%N/A0 $0.58 4/30/2020191,600 shares $101,548.00 +787.0%N/A0.6 $0.53 4/15/202021,600 shares $10,584.00 -83.4%N/A0.1 $0.49 3/31/2020130,400 shares $70,416.00 -52.7%N/A0.3 $0.54 3/13/2020275,700 shares $137,850.00 +58.3%N/A0.6 $0.50 2/28/2020174,200 shares $64,454.00 +60.9%N/A0.8 $0.37 ATBPF Short Interest - Frequently Asked Questions What is Antibe Therapeutics' current short interest? Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 8,600 shares of ATBPF short. Learn More on Antibe Therapeutics' current short interest. Is Antibe Therapeutics' short interest increasing or decreasing? Antibe Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 8,600 shares, a decrease of 86.8% from the previous total of 65,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Antibe Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Antibe Therapeutics: PepGen Inc. (2.57%), Eliem Therapeutics, Inc. (2.22%), Abliva AB (publ) (0.00%), Spero Therapeutics, Inc. (0.69%), Ovid Therapeutics Inc. (1.59%), Provectus Biopharmaceuticals, Inc. (0.00%), KALA BIO, Inc. (3.27%), Barinthus Biotherapeutics plc (0.04%), Kezar Life Sciences, Inc. (1.25%), FibroBiologics, Inc. (6.80%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Antibe Therapeutics stock? Short selling ATBPF is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Antibe Therapeutics? A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPF, which in turn drives the price of the stock up even further. How often is Antibe Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPF, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies PepGen Short Interest Data Eliem Therapeutics Short Interest Data Abliva AB (publ) Short Interest Data Spero Therapeutics Short Interest Data Ovid Therapeutics Short Interest Data Provectus Biopharmaceuticals Short Interest Data KALA BIO Short Interest Data Barinthus Biotherapeutics Short Interest Data Kezar Life Sciences Short Interest Data FibroBiologics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ATBPF) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATBPF Stock Alerts